Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477207 | 0.89 | TRPA1 (0.35) | TRPA1ALDH1A1TSHR | |
| SCHEMBL25414124 | 0.77 | ALDH1A1 (0.41) | NPC1RAB9ARELATRPA1KMT2A | |
| SCHEMBL7091307 | 0.71 | ESRRA (0.30) | — | |
| SCHEMBL4522331 | 0.70 | ALDH1A1 (0.40) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4423511 | 0.70 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4640924 | 0.69 | TRPA1 (0.56) | NPC1RAB9ASMN1; SMN2TRPA1KMT2A | |
| SCHEMBL1165944 | 0.69 | CYP3A4 (0.41) | NPC1SMN1; SMN2KMT2AALDH1A1TSHR | |
| SCHEMBL6989900 | 0.69 | NOTUM (0.33) | — | |
| SCHEMBL8024700 | 0.68 | TP53 (0.36) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4482171 | 0.67 | NPC1 (0.37) | NPC1NFKB1RAB9ANFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429587-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-07-05 | — | — | US | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7084139-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor Xa | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | NPC1 3459/4885NFKB1 458/4885RAB9A 2038/4885 |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | NPC1 607/4885NFKB1 1710/4885RAB9A 3802/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | NPC1 2129/4885NFKB1 649/4885RAB9A 2623/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | NPC1 960/4885NFKB1 2073/4885RAB9A 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.